[Differenciated thyroid cancer: management and indication of the new targeted therapies].
The emergence of the new targeted therapies has revolutionized the management of several cancers. We take a special interest in the standard management of all thyroid cancer, except the anaplasic variant. Based on two clinical cases, we examine the place of tyrosin kinase inhibitors in unusual, refractory, situations, i.e. iodine-refractory or metastatic cancer. The ideal medical approach implies a multidisciplinary teamwork.
Service d'oncologie-hématologie, Hôpital du Valais, CHCVs site de Sion, Avenue du Grand-Champsec 80, 1951 Sion. tiphaine.krahenbuhl@hopital-riviera.ch
Tiphaine
T
Krahenbuhl
Luc
L
Portmann
Sandro
S
Anchisi
D000368:Aged; D002277:Carcinoma / Q000175:diagnosis / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D002454:Cell Differentiation / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D058990:Molecular Targeted Therapy / Q000379:methods / Q000706:statistics & numerical data*; D009362:Neoplasm Metastasis; D011379:Prognosis; D012008:Recurrence; D012307:Risk Factors; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000209:etiology / Q000473:pathology / Q000628:therapy*